



Xgene Pharmaceutical Pty Ltd. Receives HREC's approval to initiate a First-In-Human (FIH) trial of its innovative analgesic product XG2002

Xgene Pharmaceutical Pty Ltd. today announced that the Company has received approval from Bellberry Human Research Ethics Committee (HREC) to conduct a First-In Human Trial in Healthy Volunteers.

XG2002, a selective novel TRPM8 channel blocker, shows compelling pain suppression effects in multiple animal pain disease models, demonstrating clean safety profile including in the cardiovascular, central nervous and respiratory systems in various toxicology studies. This novel analgesic holds great potential for treating various acute and chronic pain disorders, including neuropathic pain such as migraine, diabetic neuropathy, etc.

The Phase I dose-ascending trial will assess XG2002's tolerability and pharmacokinetic properties in healthy volunteers, providing crucial data for subsequent clinical trials.

Dr. Leon Jiang, Chief Medical Officer and Senior Vice President of Xgene Pharmaceutical Pty Ltd explained that given the substantial unmet clinical needs for acute and chronic pain management, XG2002, an analgesic on a novel target, is expected to have its unique responding population for various painful disorders, thus complementing the analgesic pipelines such as XG005 and XG004 that Xgene is developing.

Dr. Feng Xu, Co-founder, Chief Operating Officer and Chief Scientific Officer of Xgene Pharmaceutical Pty Ltd, emphasized the scarcity of innovation in pain management compared to oncology, despite the 20% global population affected by pain disorders. The company's product pipeline focuses on oral and topical non-opioid analgesics, aiming to enhance compliance in both inpatient and outpatient settings while circumventing clinical challenges associated with opioid use, such as addiction and appetite suppression. Dr. Xu expressed anticipation for high-quality clinical data from the company's analgesic pipeline, aiming to fulfill the fundamental need of pain relief for patients.

Dr. Gene Hsu, Founder and CEO of Xgene Pharmaceutical Pty Ltd, highlighted the increasing emphasis on patients' quality of life in clinical practice. The company remains dedicated to analgesic product development, striving to offer economically efficient and safer options for clinicians, thereby contributing to advancements in pain management.

About Xgene

Xgene Pharmaceutical Pty Ltd. is a subsidiary of the Xgene parent company, registered in Australia. Xgene Pharmaceutical Inc. is a clinical stage, venture capital-backed, international company utilizing proprietary linker technology to create novel, multimodal, conjugated molecules for the treatment of pain and other neurological disorders. Xgene's proprietary link technology, tailored to the recognized profiles of specific existing and newly discovered drugs, overcomes the challenges of the multimodal drug combination approach, and offers potentially better, safer, and more efficient treatments. Current programs are focused on improving the efficacy and tolerability of pain therapeutics with a pipeline comprising late-stage clinical programs as well as assets in discovery and preclinical development. Xgene has gained recognition and support from leading investment institutions such as Morningside Capital, TF Capital, Ping'an Venture Capital, Hengxu Capital, CITIC Securities and other investment institutions.